Joe Price, Jennifer Dukart, Denise Kettelberger, and Bridget Ahmann have been named among the winners of the 2012 Burton Award for Legal Achievement for their article "Product Liability Biologics and Biosimilars." The program—run in association with the Library of Congress and its law library—announced the thirty-five winning entries for best law firm writers based on nominations submitted by the nation's 1,000 largest and most prestigious law firms.
The article takes as its point of departure the Biologics Price Competition and Innovation Act (BPCIA) that established an abbreviated pathway for FDA approval of "biosimilars," often considered the generic form of "biologics." Biologics are therapeutic products used to treat a wide variety of diseases, including cancer and immune disorders, and represent a large and fast-growing segment of health care therapies. The authors forecast the potential product liability implications of the BPCIA and its proposed regulations. Their analysis guides litigation and legislative responses by biologics companies in this novel arena.
The Burton Award winners will be honored at an awards ceremony on June 12 at the Library of Congress in Washington, D.C. The program will feature United States Supreme Court Justice Stevens (retired), who is also the guest of honor.
Joe Price's practice focuses almost exclusively in the area of complex litigation, mass tort and class action products liability defense, especially litigation involving medical devices and pharmaceuticals. Bridget Ahmann and Jennifer Dukart are also members of Faegre Baker Daniels' nationally ranked products liability area, pursuing complex litigation and appellate work on matters involving pharmaceutical and medical devices. Denise Kettelberger's practice lies in intellectual property law, where she concentrates on strategic patent portfolio management for clients in the biotechnology, pharmaceutical, agricultural and medical device industries.